TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18720937
Drug: Somatostatin 6
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 6 mg/day added to TPN
Study: 18720937
Drug: Pre-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment serum level
Study: 18720937
Drug: Post-treatment serum
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment serum level
Study: 12447222
Drug: No. 23
Normalized name: vehicle base no. 23
Approvals — FDA: no, EMA: no, PMDA: no
Description: No. 23 dental explorer and air-water spray
Study: 10955129
Drug: Propafenone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 600 mg as a first oral dose followed after 8 hrs by 150 mg (Group A)
Study: 10955129
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg as a first dose, followed by the same dose 3 and again 8 hrs later (Group B)
Study: 10955129
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg every 3 hrs, up to a total dose of 600 mg (Group C)
Study: 8551493
Drug: Celiprolol therapy
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol therapy
Study: 29017497
Drug: Vildagliptin (DPP-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (DPP-4 inhibitor) add-on group
Study: 29017497
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (double dose)
Study: 21910074
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis combined with hydroxychloroquine sulfate tablet (HCQ) for 3 months
Study: 21910074
Drug: Hydroxychloroquine sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate tablet (HCQ) only for 3 months
Study: 11079363
Drug: Trazodone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 200 mg/day
Study: 6328288
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding with adequate vitamin D and phosphate supplementation
Study: 6328288
Drug: Parenteral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral feeding with vitamin D supplementation
Study: 25862567
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel
Study: 24691218
Drug: Web-based physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based physiotherapy (12 weeks, twice per week)
Study: 22015737
Drug: Benzocaine 8
Normalized name: benzocaine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine 8 mg lozenge
Study: 20039221
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg . kg(‐1)
Study: 12100764
Drug: Salbutamol metered-dose
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol metered-dose inhaler (MDI) 1.2 mg
Study: 12100764
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of salbutamol 1.2 mg
Study: 8767529
Drug: Melphalan/prednisone (MP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan/prednisone (MP) as first-line treatment in 84 patients (74%)
Study: 1858732
Drug: Rice flour
Normalized name: Rice Flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice flour solution
Study: 1858732
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organization rehydration solution by gastric infusion
Study: 1858732
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organization rehydration solution orally
Study: 31514186
Drug: Increased antiphosphatidylserine
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased antiphosphatidylserine antibodies (aPS) in patients with abnormal renal function
Study: 31514186
Drug: Increased antiphosphatidylserine
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased antiphosphatidylserine antibodies (aPS) in patients with normal renal function
Study: 26806045
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (3 g/d)
Study: 24886151
Drug: Supported cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported cognitive behavioral therapy self-help (CBTsh) supported by mental health paraprofessionals
Study: 22424003
Drug: Routine supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine supplemental oxygen therapy
Study: 17931241
Drug: Gentamicin-collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen implant (10 cm x 10 cm)
Study: 17931241
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gentamicin-collagen implant)
Study: 16219105
Drug: Chemoradiation using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine infusions weekly over 4 weeks.
Study: 16219105
Drug: Chemoradiation using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks.
Study: 7318340
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2.25 mmol of Na+/kg) over 30 min
Study: 26551051
Drug: Sofosbuvir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 12 weeks
Study: 26551051
Drug: Sofosbuvir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 12 weeks
Study: 26551051
Drug: Sofosbuvir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 25 mg plus ribavirin for 8 weeks
Study: 26551051
Drug: Sofosbuvir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 8 weeks
Study: 26551051
Drug: Sofosbuvir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 100 mg plus ribavirin for 8 weeks
Study: 26551051
Drug: Sofosbuvir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 8 weeks
Study: 21537591
Drug: Oxa-Gel
Normalized name: (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxa-Gel
Study: 19281503
Drug: Immediate transmucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate transmucosal tapered-effect (TE) implants placed in molar extraction sockets with buccal bone dehiscence
Study: 19281503
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in healed molar sites (control sites)
Study: 11678784
Drug: Oxy-XL 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy-XL 10 mg
Study: 11678784
Drug: IR-Oxy 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR-Oxy 5 mg
Study: 9832663
Drug: Warmed saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed saline solution
Study: 8076768
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment (8.4-336 MU)
Study: 8076768
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment (336 MU)
Study: 8076768
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment protocols (lower dosages)
Study: 2642538
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy for 1 year
Study: 2642538
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone for 1 year
Study: 322648
Drug: Timolol 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 1.5% solution
Study: 22908891
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone during induction of anesthesia
Study: 22908891
Drug: Short-course oral
Normalized name: short ragweed pollen extract Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course oral third-generation cephalosporin after ceftriaxone until nephrostomy catheter withdrawal
Study: 21660077
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg/day for 12 months (n = 10)
Study: 21660077
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneously twice daily) for 12 months (n = 11)
Study: 11566520
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of dexamethasone
Study: 11566520
Drug: No subconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subconjunctival steroid injection
Study: 9626918
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of formoterol
Study: 3585263
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic ointment (neomycin, polymyxin B, bacitracin) applied twice a day
Study: 3585263
Drug: Other antibiotic
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotic ointment
Study: 21034744
Drug: Telaprevir 750
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg every 8 hours with peginterferon alfa-2a and ribavirin
Study: 21034744
Drug: Telaprevir 1125
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 1125 mg every 12 hours with peginterferon alfa-2a and ribavirin
Study: 12568736
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (Premelle)
Study: 8725417
Drug: Midazolam at
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam at a target plasma concentration of 150 ng/mL
Study: 8725417
Drug: Midazolam at
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam at a target plasma concentration of 300 ng/mL
Study: 1561909
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg/d
Study: 3898348
Drug: Anticholinergic (glycopyrrolate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic (glycopyrrolate, 2 mg three times daily) and antacid (60 ml/day)
Study: 3898348
Drug: Anticholinergic/antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic/antacid
Study: 30539891
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IFA tablets without direct supervision)
Study: 22538329
Drug: Intensive low-density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive low-density lipoprotein cholesterol and blood pressure lowering therapy
Study: 17158415
Drug: 400,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400,000 IU vitamin A in 2 divided doses
Study: 17158415
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU vitamin A as a single dose plus placebo
Study: 17158415
Drug: Post-treatment serum
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment serum retinol concentrations
Study: 10884642
Drug: Controlled injection
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled injection pressure system
Study: 10884642
Drug: Conventional atraumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional atraumatic syringe injection technique
Study: 1593854
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.55 g/kg/day)
Study: 1593854
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (2 g/kg/day)
Study: 6140202
Drug: High-dose 6-methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 6-methylprednisolone
Study: 6140202
Drug: 6-methylprednisolone combined
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-methylprednisolone combined with 3 g of sulfasalazine
Study: 6140202
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of sulfasalazine alone
Study: 6140202
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of low doses of 6-methylprednisolone or the combination regimen
Study: 30880285
Drug: CRP-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-guided antibiotic treatment (CRP ≥50 mg·L‐1)
Study: 30880285
Drug: CRP-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-guided antibiotic treatment
Study: 29059190
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass drug administration (MDA) of praziquantel
Study: 17299107
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing green tea catechins, caffeine, and calcium (3 x 250-mL servings for 3 days)
Study: 11243304
Drug: Plasma leptin
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma leptin levels (mean, 11.1 ng/mL for boys and 19.7 ng/mL for girls in the highest quintile)
Study: 8153985
Drug: Albendazole 600
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 600 mg single dose
Study: 8153985
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg single dose
Study: 8153985
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg daily for 3 days
Study: 8613282
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg daily for 5 days
Study: 2896600
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (1.5 mg/kg/day for one year)
Study: 31030594
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (terbinafine 250 mg + itraconazole 200 mg)
Study: 31664782
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg
Study: 8527290
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg
Study: 29737494
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 500 mg (1, 3)(1, 6)-β-glucan (BG) daily
Study: 28430976
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg single dose)
Study: 28430976
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg/day for 21 days)
Study: 21435141
Drug: 10-mg dapagliflozin
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg dapagliflozin fed (high-fat meal)
Study: 21435141
Drug: 10-mg dapagliflozin
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg dapagliflozin fasted
Study: 16827738
Drug: Titanium abutment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium abutment with cemented implant-supported single-tooth crown
Study: 16827738
Drug: Gold-alloy abutment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold-alloy abutment with cemented implant-supported single-tooth crown
Study: 12723857
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy (S), nonsteroid anti-inflammatory with orphenadrine citrate (O), and benzodiazepine (B)
Study: 10786738
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/ml for infiltration of trocar sites (Group B)
Study: 10786738
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg i.v. (Group T)
Study: 8440094
Drug: Lovastatin (up-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (up-titrated from 20 mg to 80 mg/day during the first 16 weeks)
Study: 3527514
Drug: Tripamide 10
Normalized name: xipamide
DrugBank: Xipamide (DB13803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripamide 10 mg
Study: 3527514
Drug: Tripamide 25
Normalized name: xipamide
DrugBank: Xipamide (DB13803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripamide 25 mg
Study: 3527514
Drug: Tripamide 50
Normalized name: xipamide
DrugBank: Xipamide (DB13803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripamide 50 mg
Study: 3527514
Drug: Tripamide 100
Normalized name: xipamide
DrugBank: Xipamide (DB13803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripamide 100 mg
Study: 9184268
Drug: Antidepressant drugs
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drugs
Study: 25502581
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg orally daily for 12 months)
Study: 25502581
Drug: Losartan (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (in vitro treatment)
Study: 25502581
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg orally daily for 12 months)
Study: 25502581
Drug: Amlodipine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (in vitro treatment)
Study: 18268422
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy applied by nasal prongs
Study: 10695905
Drug: Opioid bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid bolus regimen (7.5 microg x kg(‐1) fentanyl, 70% N2O, with 2.5 microg x kg(‐1) supplements as needed)
Study: 10695905
Drug: Opioid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid infusion (Alfentanil 50 microg x kg(‐1) bolus, 1‐1.5 microg x kg(‐1) x min(‐1) infusion, 70% N2O)
Study: 9082104
Drug: Topical cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cefazolin (group 2)
Study: 9082104
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin (group 1)
Study: 30429144
Drug: Zero-balance goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zero-balance goal-directed fluid therapy (GDT)
Study: 26272051
Drug: Dutasteride (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (low-dose 0.5 mg/day)
Study: 26272051
Drug: Dutasteride (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (high-dose 2.5 mg/day)
Study: 19490746
Drug: Psychosocial family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial family intervention, individual counselling and standard treatment
Study: 19490746
Drug: Individual counselling
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual counselling and standard treatment
Study: 17295567
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg) plus group behavioral quit‐smoking treatment for 12 weeks
Study: 17295567
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus group behavioral quit‐smoking treatment for 12 weeks
Study: 11350324
Drug: Bupivacaine field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine field block administered after induction but before surgery
Study: 11350324
Drug: Bupivacaine field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine field block administered after surgery but before the end of anaesthesia
Study: 3131041
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NTG) at doses ranging from 10 to 120 micrograms/min (mean = 52 +/- 33 micrograms/min)
Study: 3135734
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NTG)
Study: 3131041
Drug: Sublingual NTG
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual NTG (0.4 mg) as a positive control
Study: 18240348
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus ecabet sodium (group B)
Study: 18240348
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (group A)
Study: 16999353
Drug: Edgewise appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Edgewise appliance combined with flat bite plate treatment